Actively Recruiting

Age: 18Years +
All Genders
NCT05136807

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Led by M.D. Anderson Cancer Center · Updated on 2026-04-15

400

Participants Needed

1

Research Sites

556 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.

CONDITIONS

Official Title

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with monoclonal gammopathy of unknown significance aged 18 years or older.
  • Serum monoclonal protein less than 3 g/dL or urinary monoclonal protein less than 500 mg per 24 hours and clonal bone marrow plasma cells less than 10%.
  • No myeloma defining events or amyloidosis.
  • OR patients with smoldering multiple myeloma aged 18 years or older.
  • Serum monoclonal protein 3 g/dL or higher or urinary monoclonal protein 500 mg or higher per 24 hours and/or clonal bone marrow plasma cells 10-60%.
  • No myeloma defining events or amyloidosis.
  • Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer Center.
  • Patients must speak English or Spanish.
Not Eligible

You will not qualify if you...

  • Evidence of myeloma defining events or biomarkers of malignancy including hypercalcemia, renal insufficiency, anemia, bone lesions, clonal bone marrow plasma cells 60% or higher, involved:uninvolved serum free light chain ratio 100 or higher, or more than 1 focal lesion on MRI.
  • Plasma cell leukemia.
  • Presence of cognitive impairment or delirium as determined by the primary clinician.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

M

Melody Becnel, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here